In our daily life we interact with many different people who help us by applying their expertise to deliver things we would otherwise struggle with. Often the differentiator for us, as consumers, is how we feel we’ve been treated by the people who are working on our behalf. The first…

Along with a series of studies we plan to present related to our experiences with hybrid LC-MS/MS technology, KCAS will also be presenting on a study where we analyzed a compound that involved looking at urea in plasma and lung fluid (urea, of course, being a biomarker). Urea is endogenous…

For years, Dawn Dufield, PhD and I have been doing our best to get the word out (via as many venues as possible) about KCAS’s unique expertise with hybrid LC-MS/MS. This year’s upcoming EBF meeting in Barcelona is just such an opportunity, and one we are very much looking…

The Pharm/Biotech industry’s main focus is on development of therapeutics to address unmet medical needs but sometimes, clinical trials lead to observations that lead to a change in research path for a drug. A good example is sildenafil that was originally studied for use in hypertension and angina pectoris. Observed…

Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or biologics and Anti-Drug Antibodies (ADA). Throughout the development of New…

In the ever-evolving landscape of pharmaceutical research, biodistribution studies play a pivotal role in understanding how drugs and therapies are distributed within the body. These studies are critical for assessing the efficacy and safety of new treatments, particularly in the realm of cell…

Recently, Matthew Pennington, PhD (one of KCAS’s Senior Scientists) was the senior author on a publication entitled “A Validated Droplet Digital Polymerase Chain Reaction Assay for the Detection of Adeno Associated Viral Vectors in Bio Shedding Studies of Tears”. Below, Matt explains the significance in what they accomplished…

In the rapidly evolving realm of flow cytometry, conventional flow cytometry is gradually being displaced by its advanced counterpart, spectral flow cytometry. These technologies, each with its unique strengths and applications, have revolutionized the way we analyze cells and particles. Let’s dive…

A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention, including therapeutic interventions(1). With the development of innovative and personalized therapies, biomarker tracking is increasingly important to support the clinical development…

Immunophenotyping has undergone a seismic change in less than two decades as panel sizes have increased in complexity from <10 to >40 colors. Let’s explore how immunophenotyping is transforming the field and how FlowMetric, a KCAS…

In an exciting development, KCAS, through its subsidiary FlowMetric, is expanding its flow services in Europe. With a history of providing cutting-edge flow services in the EU, KCAS is taking a significant step forward by transitioning services from its Milan, Italy site to…

With recent guidance released from the FDA, there are changes for PKs (Pharmacokinetics) and ADCs (Antibody Drug Conjugates) that must be clearly understood before making decisions for your drug product testing. ADCs combine the target specificity of monoclonal antibodies with the…